BIOLOGICS OUTSOURCING MARKET ANALYSIS

Market News

Global Biologics Outsourcing Market: Key Developments

In August 2021, Yposkesi, a contract development and manufacturing organization (CDMO), announced construction of its second commercial facility to manufacture cell and gene therapies at its campus in Corbeil-Essonnes, France. The facility will increase the company’s manufacturing capacity to meet growing demand for gene therapy treatments for rare and common diseases, as well as supporting its expansion in the global biologics outsourcing market.

In May 2021, WuXi Biologics, a CDMO, and OncoC4, Inc., a clinical-stage biopharmaceutical company, announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late stage project, ONC-392, a next generation CTLA-4 antibody, which is under phase I clinical trials in the U.S. and China.

In October 2022, SAB Biotherapeutics, a clinical-stage biopharmaceutical company, announced partnership with Emergent, a CDMO. Emergent will provide contract development and manufacturing (CDMO) services to produce SAB’s fully-human polyclonal antibody products.

In September 2022, Abzena Ltd, announced an upgradation of its research and development capabilities in England, U.K. The company strengthens research and development capabilities by investment and implementation of primary B cell antibody discovery technologies named Berkley Lights’ Beacon system that supports rapid antibody discovery, by isolating single B cells from a target-primed cohort of lymphocytes.

In June 2022, Curia Global, Inc. a contract research and manufacturing organization, adopted Beacon Optofluidic system and workflows from Berkeley Lights, Inc., a digital cell biology company, to expand and accelerate its antibody-based drug discovery capabilities.